Top

Published in:

01-09-2003 | Original Article

Peptides designed from molecular modeling studies of the ras-p21 protein induce phenotypic reversion of a pancreatic carcinoma cell line but have no effect on normal pancreatic acinar cell growth

Authors: Mecheal Kanovsky, Josef Michl, Georgia Botzolaki, Joseph Morin, Cecilia Kovac, Denise L. Chung, Lyndon Chie, Fred K. Friedman, Matthew R. Pincus

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2003

Abstract

Purpose

From molecular modeling studies we found that two ras-p21 peptides, corresponding to p21 residues 35–47 (PNC-7) and 96–110 (PNC-2), selectively block oncogenic (Val 12-p21), but not insulin-activated wild-type, p21-induced oocyte maturation. Our purpose was to determine if these peptides block the growth of mammalian cancer cells but not their normal counterpart cells.

Methods

Since oncogenic ras has been implicated as a causative factor in over 90% of human pancreatic cancers, we have established a normal pancreatic acinar cell line (BMRPA1) and the corresponding ras-transformed pancreatic cancer cell line (TUC-3). We treated both cell lines with PNC-7 and PNC-2 and the unrelated negative control peptide, X13, attached to the penetratin sequence that allows membrane penetration and also transfected these cell lines with plasmids encoding all three peptides.

Results

Treatment of TUC-3 cells with each peptide resulted in their complete phenotypic reversion to the untransformed phenotype as revealed by the lack of tumor formation of these revertant cells implanted in the peritoneal cavities of nude mice. In contrast, treatment with X13-leader resulted in no inhibition of cell growth. Identical results were obtained when TUC-3 cells were transfected with plasmids expressing PNC-2, PNC-7 and X13. None of these peptides affected the normal growth of BMRPA1 cells.

Conclusions

PNC-2 and PNC-7 peptides induce phenotypic reversion of ras-induced pancreatic cancer cells and have no effect on normal pancreatic cell growth. Since the plasmid encoding PNC-2 without penetratin also had the same effect on the TUC-3 cell line, we conclude that the penetratin sequence has no effect on the activity of this peptide. Since X13 attached to penetratin had no effect on TUC-3 cells, the effect is specific for PNC-2 and PNC-7 and further confirms that the effect is not caused by the penetratin sequence. PNC-2- and PNC-7-penetratin may therefore be useful in the treatment of ras-induced pancreatic carcinomas.

Barbacid M (1987) ras Genes. Annu Rev Biochem 56:779–827PubMed

Pincus MR, Brandt-Rauf PW, Koslosky W, Appruzzese W (2001) Cell biology and early tumor detection. In: Henry JB (ed) Clinical diagnosis and management by laboratory methods, 19nth edn. WB Saunders, Philadelphia, pp1344–1354

Birchmeier C, Broek D, Wigler M (1985) ras proteins can induce meiosis in Xenopus oocytes. Cell 43:615–621PubMed

Deshpande AK, Kung H-F (1987) Insulin induction of Xenopus laevis oocyte maturation is inhibited by monoclonal antibody against p21 ras proteins. Mol Cell Biol 7:1285–1288PubMed

Pincus MR, Brandt-Rauf PW, Michl J, Friedman FK (2000) ras-p21-Induced cell transformation: unique signal transduction pathways and implications for the design of new chemotherapeutic agents. Cancer Invest 18:39–50PubMed

Chen JM, Monaco R, Manolatos S, Brandt-Rauf PW, Friedman FK, Pincus MR (1997) Molecular dynamics on complexes of ras-p21 and its inhibitor protein, rap-1A, bound to the ras-binding domain of the raf-p74 protein. Identification of effector domains in the raf protein. J Protein Chem 16:631–635PubMed

Chung D, Amar S, Glozman A, Chen JM, Friedman FK, Robinson R, Monaco R, Brandt-Rauf PW, Yamaizumi Z, Pincus MR (1997) Inhibition of oncogenic and activated wild-type ras-p21 protein-induced oocyte maturation by peptides from the ras binding domain of the raf-p74 protein, identified from molecular dynamics calculations. J Protein Chem16:619–629

Chen JM, Rijwani K, Friedman FK, Hyde MJ, Pincus MR (2000) Identification, using molecular dynamics, of an effector domain of the ras-binding domain of the raf-p74 protein that is uniquely involved in oncogenic ras-p21 signaling. J Protein Chem 7:543–549

Chen JM, Friedman FK, Hyde MJ, Monaco R, Pincus MR (2000) Molecular dynamics analysis of the structures of ras-guanine nucleotide exchange protein (SOS) bound to wild-type and oncogenic-ras-p21. Identification of effector domains of SOS. J Protein Chem 18:867–874CrossRef

10.

Chie L, Chen JM, Friedman FK, Chung DL, Amar S, Michl J, Yamaizumi Z, Pincus MR (2000) Inhibition of oncogenic and activated wild-type ras-p21 protein-induced peptides from the guanine-nucleotide exchange protein, SOS, identified from molecular dynamics calculations. Selective inhibition of oncogenic ras-p21. J Protein Chem 18:875–879CrossRef

11.

Adler V, Pincus MR, Brandt-Rauf PW, Ronai Z (1995) Complexes of ras-p21 with jun-N-kinase and c-jun proteins. Proc Natl Acad Sci U S A 92:10585–10589PubMed

12.

Adler V, Pincus MR, Polatskaya A, Montano X, Friedman FK, Ronai Z (1996) Activation of c-jun NH₂ terminal kinase by UV irradiation is dependent on p21^ras. J Biol Chem 271:23304–23309PubMed

13.

Chung DL, Joran A, Friedman FK, Robinson RR, Brandt-Rauf PW, Weinstein IB, Ronai ZA, Baskin L, Dykes DC, Murphy RB, Nishimura S, Yamaizumi Z, Pincus MR (1992) Evidence that oocyte maturation induced by an oncogenic ras p21 protein and insulin is mediated by overlapping yet distinct mechanisms. Exp Cell Res 203:329–335PubMed

14.

Chie L, Friedman FK, Kung H-F, Lim MCM, Chung DL, Pincus MR (2002) Identification of the site of inhibition of mitogenic signaling by oncogenic ras-p21 by a ras effector peptide. J Protein Chem 21:367–370CrossRefPubMed

15.

Chie L, Chen JM, Friedman FK, Chung DL, Amar S, Michl J, Yamaizumi Z, Brandt-Rauf PW, Pincus MR (2000) Identification of the site of inhibition of oncogenic ras-p21-induced signal transduction by a peptide from a ras effector domain. J Protein Chem 18:881–884CrossRef

16.

Way D, Smith S, Sivendran S, Kanovsky M, Brandt-Rauf PW, Chung DL, Michl J, Pincus MR (2002) A protein kinase C inhibitor induces phenotypic reversion of ras-transformed pancreatic cancer cells and cooperatively blocks tumor cell proliferation with an anti-ras peptide. Cancer Chemother Pharmacol 49:429–437CrossRefPubMed

17.

Bao LY, Thelmo WL, Somnay S, Madahar C, Michl J (1994) Characterization of an acinar cell line, BMRPA.430, derived from adult rat pancreas. FASEB J 8:64A

18.

Almoguerra C, Shibata D, Forrester K, Martin J, Arnheim M, Perucho M (1988) Most human carcinomas of the endocrine pancreas contain mutant c-K-ras genes. Cell 53:813–815

19.

Derossi D, Chassaing G, Prochiantz A (1998) Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol 8:84–87CrossRefPubMed

20.

Kanovsky M, Raffo A, Drew L, Rosal R, Do T, Friedman FK, Rubinstein P, Visser I, Robinson R, Brandt-Rauf PW, Michl J, Fine RL, Pincus MR (2001) Peptides from the amino terminal mdm-2 binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc Natl Acad Sci U S A 98:12438–12443CrossRefPubMed

21.

Kovac C, Chie L, Morin J, Friedman FK, Robinson R, Chung DL, Kanovsky M, Flom J, Brandt-Rauf PW, Yamaizumi Z, Michl J, Pincus MR (2000) Plasmid expression of a peptide that selectively blocks oncogenic ras-p21-induced oocyte maturation. Cancer Chemother Pharmacol 45:441–449CrossRefPubMed

22.

Shindo-Okada N, Makabe O, Nagahara H, Nishimura S (1989) Permanent conversion of mouse and human cells transformed by activated ras or raf genes to apparently normal cells by treatment with the antibiotic azatyrosine. Mol Carcinog 2:159–167PubMed

23.

Contente S, Kenyon K, Rimoldi D, Friedman RM (1990) Expression of gene rrg is associated with reversion of NIH 3T3 transformed by LTR-c-H-ras. Science 249:796–798PubMed

24.

Meyer T, Regenass U, Fabbro D, Alteri E, Rosel J, Muller M, Caravatti G, Matter A (1989) A derivative of staurosporine (CPG 41 251) shows selectivity for protein kinase C inhibition and in vivo anti-tumor activity. Int J Cancer 43:851–856PubMed

25.

Chung D, Villafania A, Anwar K, Amar S, Rijwani K, Kung H-F, Adler V, Ronai Z, Brandt-Rauf PW, Yamaizumi Z, Pincus MR (1998) Mutual dependence of jun-N-terminal kinase and protein kinase C on the oncogenic ras-p21 protein-induced mitogenic signaling pathway. Med Sci Res 26:147–150

Title: Peptides designed from molecular modeling studies of the ras-p21 protein induce phenotypic reversion of a pancreatic carcinoma cell line but have no effect on normal pancreatic acinar cell growth
Authors: Mecheal Kanovsky
Josef Michl
Georgia Botzolaki
Joseph Morin
Cecilia Kovac
Denise L. Chung
Lyndon Chie
Fred K. Friedman
Matthew R. Pincus
Publication date: 01-09-2003
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2003
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-003-0639-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2003

Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders

Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy

Role of mismatch repair in the induction of chromosomal aberrations and sister chromatid exchanges in cells treated with different chemotherapeutic agents

Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer

Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1

Keynote webinar | Spotlight on antibody–drug conjugates in cancer